Technology 9 of 266
Medicinal chemistry
20 EIC Accelerator winners build on Medicinal chemistry, 2% of the classified companies, in 1 sector and 2 industries.
20
Companies
1
Sectors
2
Industries
13
Countries
0%
Exits
15%
Show signs of scaling
Sectors
- Health20 (100%)
Industries
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Medicinal chemistry
Show the numbers
| Companies | Medicinal chemistry | |
|---|---|---|
| 2019 | 2 | 2 |
| 2020 | 1 | 1 |
| 2021 | 2 | 2 |
| 2022 | 7 | 7 |
| 2023 | 7 | 7 |
| 2024 | 1 | 1 |
What happened to them (20 of 20 checked)
- Active17 (85%)
- Exit0 (0%)
- Failed3 (15%)
- Other0 (0%)
Signs of scaling
- Scaling3 (15%)
- Not scaling6 (30%)
- Scaling unclear11 (55%)
Keywords
- Addiction
- Adenosine receptors
- Airway inflammation
- Alcohol use disorder
- Alzheimer's disease
- Amputation prevention
- Antimicrobial resistance
- Antithrombotics
- Antivirals
- Autophagy
- Autotaxin inhibitors
- Bacterial infections
- Beta-lactamase inhibitors
- Blood-brain barrier
- Brain cancer
- Broad-spectrum antivirals
- Cancer immunotherapy
- Cancer metastasis
- Carbapenem-resistant bacteria
- Cardiology
- Checkpoint inhibitors
- Chemotherapy combination
- Chronic limb-threatening ischaemia
- Cognitive decline
- COPD
- Delta opioid receptor
- Dengue
- Dialysis access
- Down syndrome
- Drug repurposing
- Early intervention
- Fibrosis
- Fixed-dose combination
- Inflammation
- Lung cancer
- Marine natural products
- Oncology
- Opioid alternatives
- Pain
- Pancreatic cancer
All 20 companies using Medicinal chemistry
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| PharmNovo AB | PN6047-DOBRAPN6047 - a breakthrough treatment of neuropathic pain | Biopharmaceuticals | Sweden | March 2024 | Blended finance | Active | Deep dive |
| RESOTHER PHARMA APS | CardioProtectMIA new cardioprotective drug for acute treatment of myocardial infarction | Biopharmaceuticals | Denmark | June 2023 | Grant first | Active | Deep dive |
| REST THERAPEUTICS | FENM4PTSDDevelopment of a novel class of therapeutics for PTSD treatment and other neurodegenerative disorders | Biopharmaceuticals | France | June 2023 | Grant first | Active | Deep dive |
| SEA4US - BIOTECNOLOGIA E RECURSOS MARINHOS, S.A. | Sea4MarketClinical validation of a novel non-opioid analgesic derived from the Portuguese sea for treating chronic pain | Biopharmaceuticals | Portugal | June 2023 | Blended finance | Active | Deep dive |
| Celtic Biotech Ltd | CB24Development of a natural therapeutic treatment for late-stage lung cancer patients | Biopharmaceuticals | Ireland | March 2023 | Grant first | Active | Deep dive |
| Convert Pharmaceuticals S.A. | TUMAGNOSTICA disruptive hypoxia activated prodrug for the treatment of resistant cancers: an AI-driven approach | Biopharmaceuticals | Belgium | March 2023 | Blended finance | Active | Deep dive |
| GeneCode AS | KevadBioDeveloping a novel Parkinson's disease drug using small molecule mimetics of Glial cell line-Derived Neurotrophic Factor (GDNF) | Biopharmaceuticals | Estonia | March 2023 | Grant first | Active | Deep dive |
| PamGene International BV | ROUTINEcanceR agnOstic immUnoTherapy predIctioN blood-tEst | In vitro diagnostics | Netherlands | March 2023 | Blended finance | Active | Deep dive |
| iOnctura BV | CURE-PDACCURE-PDAC | Biopharmaceuticals | Netherlands | October 2022 | Blended finance | Active | Deep dive |
| Protinhi B.V. | ATLASThe first broad-spectrum treatment against pandemic-prone flaviviral infections: Dengue, West-Nile and Zika | Biopharmaceuticals | Netherlands | October 2022 | Blended finance | Insolvent | Deep dive |
| Antabio SAS | sbli-ant3310A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO | Biopharmaceuticals | France | June 2022 | Blended finance | Active | Deep dive |
| Hemispherian AS | CureGLIOClinical validation of GLIX1: a small molecule that targets epigenetic changes in cancer cells to treat glioblastoma multiforme (GBM), the highest global unmet need in oncology. | Biopharmaceuticals | Norway | June 2022 | Blended finance | Active | Deep dive |
| Meletios Therapeutics | FLUIDITYFighting Large-Scale Untreated Infectious Diseases with Innovative Treatments | Biopharmaceuticals | France | June 2022 | Blended finance | Insolvent | Deep dive |
| Aplagon Oy | APAC-ONAPAC – the first targeted therapy for peripheral arterial occlusive disease. | Biopharmaceuticals | Finland | March 2022 | Blended finance | Active | Deep dive |
| PERHA PHARMACEUTICALS SAS | DOWN-AUTONOMYLCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome. | Biopharmaceuticals | France | March 2022 | Blended finance | Active | Deep dive |
| PALOBIOFARMA, S.L | RESPIREDevelopment of the first oral disease-modifying treatment for chronic obstructive pulmonary disease (COPD) | Biopharmaceuticals | Spain | October 2021 | Blended finance | Active | Deep dive |
| PROSION GmbH | ProMThe ProM platform: New ways to drug the undruggable | Biopharmaceuticals | Germany | June 2021 | Grant first | Insolvent | Deep dive |
| Ability Pharmaceuticals SA | PanC-ASAPAbilityPharma: Accelerating Solutions for Pancreatic Cancer | Biopharmaceuticals | Spain | January 2020 | Blended finance | Active | Deep dive |
| EpiEndo Pharmaceuticals hf. | BRONCHOTHELINThe first-in-class disease-modifying drug for chronic airway disorders | Biopharmaceuticals | Iceland | October 2019 | Blended finance | Active | Deep dive |
| KINNOV THERAPEUTICS | StopAddictThe game changer drug to cure alcohol use disorders | Biopharmaceuticals | France | April 2019 | Grant only | Active | Deep dive |